Reunite™
Reunite™ is an innovative, three-step, dual-chamber cartridge autoinjector, built with our market-proven Needle isolation Technology (NIT®), designed to support automated reconstitution and delivery of lyophilized formulations.
Meet Reunite™
For lyophilized formulations
Reunite is the only mechanical autoinjector with Needle Isolation Technology (NIT®) available on the market that supports automated reconstitution and delivery of lyophilized formulations.
Specifications
- Viscosity
- Low
- Volume
- 0.5 - 0.7 mL
- Device type
- Disposable autoinjector
- Primary container
- Dual-chamber cartridge with pre-installed needle (NIT®)
- Route of administration
- Subcutaneous
- Connectivity
- No
- Dosage type
- Fixed Dose
- Activation method
- Needle cover
- Injection feedback
- Audible click at beginning of injection, viewing window
- Customization
- Yes
- Note
- Fill volume below 0.5 ml requires additional feasibility testing
Needle Isolation Technology (NIT®)
NIT® is a market-proven, pre-attached needle technology for injections that eliminates the need for patients to manually attach the needle. NIT provides complete control of cannula gauge and length to support target injection time and injection depth.
The first NIT-enabled autoinjector received regulatory approval in 2017 for a metabolic treatment. In 2024, a second device was approved for treatment of two dermatological conditions.
![[.gif] Reunite-NIT cannula ending-4k-20250915](https://cdn.bfldr.com/DTG6CG68/at/fb7w57tqhmx73vpt783rqvv3/Reunite-NIT_cannula_ending-4k-20250915.gif?width=480&height=480&fit=crop&auto=webp&format=webp)
Advancing lyophilized drug administration
Unique Offering
Reunite is the first commercialized dual-chamber cartridge, three-step autoinjector with NIT® that supports automated reconstitution and delivery of lyophilized formulations.
Automated Reconstitution
Reunite is an autoinjector that supports automated reconstitution and delivery of lyophilized formulations
Self-administration of lyophilized drugs
With automated reconstitution, Reunite enables reliable self-injection of lyophilized formulations, reducing reliance on clinic-based administration and supporting home-based care models.
Usability
Reunite features a simple, three-step process ensuring accurate dosing with a user-friendly design for safe and effortless use.
Expertise
Together with our pharma partner, we recently launched the first three-step, dual-chamber cartridge autoinjector for lyophilized formulations. It was granted marketing authorization in the US in 2024, and in the EU, UK, and Switzerland in 2025.
Flexible platform device offering
By leveraging SHL Medical’s extensive platform expertise, we can develop and manufacture devices with reduced development risks and shorter timelines.
